

**Release of Securities from Escrow Restriction**

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) advises in accordance with ASX Listing Rule 3.10A that the securities referred to below will be released from ASX escrow on or after their respective escrow expiry date, as referred to below.

Securities	Number	Escrow Expiry Date
Ordinary Fully Paid Shares	39,939,721	12 December 2020
Unlisted Options @0.25	19,022,000	12 December 2020
Unlisted Options @\$0.000002	927,504	12 December 2020

Further, the Company advises that the following securities will be released from voluntary escrow on or after their respective escrow expiry date as referred to below.

Securities	Number	Escrow Expiry Date
Ordinary Fully Paid Shares	8,277,494	5 December 2020
Ordinary Fully Paid Shares	1,628,126	12 December 2020

All shares listed above are already quoted on the ASX.

The holders to which these shares relate are considered long-term investors in the Company. Whilst the Company cannot predict the investment decision of the individual shareholders, it has been confirmed by a majority of these holders that they have no intention of divesting post-escrow.

This announcement has been authorised by the Board of HeraMED Limited.

**-ENDS-**

**HeraMED Limited**

CEO and Co-Founder

David Groberman

M: +972 52 6991188

E: [David@hera-med.com](mailto:David@hera-med.com)

**Company Secretary**

Jonathan Hart

T: +61 2 8379 2961

E: [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com)

**Media Enquiries**

Melissa Hamilton

Media & Capital Partners

M: +61 4 1775 0274

E: [Melissa.hamilton@mcpartners.com.au](mailto:Melissa.hamilton@mcpartners.com.au)

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.

**About HeraCARE**

The Company’s proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

For personal use only